CG Oncology
CGON
233 hedge funds and large institutions have $6.59B invested in CG Oncology in 2026 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 85 increasing their positions, 71 reducing their positions, and 33 closing their positions.
660% more call options, than puts
Call options by funds: $187M | Put options by funds: $24.5M
20% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 71
15% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 33
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
2% more funds holding
Funds holding: 229 → 233 (+4)
2% more capital inflows, than outflows
Capital inflows: $462M | Capital outflows: $453M
1.45% less ownership
Funds ownership: 106.37% → 104.92% (-1.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$64.9M |
| 2 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$37.6M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$31.8M |
| 4 |
EcoR1 Capital
San Francisco,
California
|
+$27.7M |
| 5 |
Morgan Stanley
New York
|
+$23.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
-$69.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$51.4M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$30M |
| 4 |
Caption Management
Oklahoma City,
Oklahoma
|
-$29.4M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$27.7M |
CGON Hedge Fund Activity: Q3 2026 in Review
233 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in CG Oncology (CGON) for Q3 2026, worth a combined $6.59B — down 1.1% from $6.66B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new CGON positions and 33 closed out — a net gain of 5 holders — while 85 added to existing stakes and 71 trimmed.
The largest buyer was Hood River Capital Management, opening a new position worth an estimated $64.9M. The largest seller was OrbiMed, exiting entirely with an estimated $69.1M sold.
- 233 institutional investors held CG Oncology (CGON) as of Q3 2026, up from 229 in Q2 2026.
- Funds reported $6.59B of CG Oncology stock for Q3 2026, down 1.1% quarter-over-quarter.
- 38 funds opened new CG Oncology positions in Q3 2026 and 33 closed out, a net change of +5 holders.
- The largest CG Oncology buyer in Q3 2026 was Hood River Capital Management, an estimated $64.9M added.
- The largest CG Oncology seller in Q3 2026 was OrbiMed, an estimated $69.1M sold.
Based on aggregated 13F filings for Q3 2026.